Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Zyrtec vs. benadryl: which allergy pill is better for MS patients before infusions?

NCT ID NCT07472413

Symptom relief Sponsor: University of Miami Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests whether cetirizine (Zyrtec) causes less sleepiness than diphenhydramine (Benadryl) when used as a pre-medication before anti-CD20 infusions for multiple sclerosis. Sixty participants will receive either drug 30-60 minutes before their infusion, and researchers will measure drowsiness and fatigue. The goal is to find a more tolerable option to prevent infusion reactions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cetirizine (Zyrtec) and diphenhydramine (Benadryl)
What this could lead to
If cetirizine works as well as diphenhydramine with less drowsiness, it could offer MS patients a more tolerable pre-medication option before their infusions.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to all MS patients. The study compares two common drugs, so no major breakthroughs are expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Ages ≥18 years * Able to read and speak in English or Spanish * Able to and willing to give informed consent * Diagnosis of Multiple Sclerosis (MS) * Patients starting or currently receiving ocrelizumab, ublituximab, rituximab Exclusion Criteria: * Adults unable or unwilling to consent * Patients younger than 18 years of age * Pregnant women * Known hypersensitivity to cetirizine or any of its ingredients or hydroxyzine * Moderate or severe renal impairment (creatinine clearance or 11-31 mL/min or worse) * Patients with prior hypersensitivity reactions on additional preventative measures (e.g. H1 and H2/proton-pump inhibitor (PPI) the night prior to the infusion due to history of reactions)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UHealth Boca Raton

    Boca Raton, Florida, 33486, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.